Last reviewed · How we verify
Panzem® NCD
At a glance
| Generic name | Panzem® NCD |
|---|---|
| Also known as | 2-methoxyestradiol, 2ME2 |
| Sponsor | CASI Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma (PHASE2)
- Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer (PHASE2)
- Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panzem® NCD CI brief — competitive landscape report
- Panzem® NCD updates RSS · CI watch RSS
- CASI Pharmaceuticals, Inc. portfolio CI